Russia's Luna-25 spacecraft crashes into Moon
21-08-2023, 06:33

Font size: [ A+ ] / [ A- ]

Russia's unmanned Luna-25 spacecraft has crashed into the Moon after spinning out of control, officials say.

It was Russia's first Moon mission in almost 50 years.

The craft was due to be the first ever to land on the Moon's south pole, but failed after encountering problems as it moved into its pre-landing orbit.

It was set to explore a part of the Moon which scientists think could hold frozen water and precious elements.

Roscosmos, Russia's state space corporation, said on Sunday morning that it had lost contact with the Luna-25 shortly after 14:57pm (11:57 GMT) on Saturday.

Preliminary findings showed that the 800kg lander had "ceased to exist as a result of a collision with the surface of the Moon", it said in a statement.

It said a special commission would look into why the mission failed.

The loss of Luna-25 is a blow to Roscosmos. Russia's civilian space programme has been in decline for several years, as state funding is increasingly directed towards the military.

Russia was racing to the Moon's south pole against India, whose Chandrayaan-3 spacecraft is scheduled to land there in the coming days and send a rover to explore the rocks and craters, gathering data and images to send back to Earth.

Parts of the Moon's south pole remain permanently in shadow, which makes finding water a possibility.

A spokesperson for the Indian space agency Isro described the Luna-25 crash as "unfortunate".

"Every space mission is very risky and highly technical. It's unfortunate that Luna-25 has crashed," they told the BBC.

Roscosmos had acknowledged that the Luna-25 mission was risky and could fail. The craft launched from Vostochny Cosmodrome in the far eastern Amur region of Russia on 11 August, and then successfully entered the moon's orbit on Wednesday of this week.

It was expected to make history by making a soft landing on Monday or Tuesday, just days before the Indian touchdown.

No country has ever landed on the Moon's south pole before, although both the US and China have landed softly on the Moon's surface.

Luna-25 was Russia's first Moon mission since 1976, when it was part of the Soviet Union. That mission, Luna-24, landed successfully.

 

BBC

Comments: 2591
#1391   Calvin
      
biggest steroid users

References:


ajarproductions.com
7 October 2025 23:25
#1390   Deon
      
Since the admin of this site is working, no
question very rapidly it will be well-known, due to its quality
contents.

my web-site; high stakes Poker
7 October 2025 23:07
#1389   Oliver
      
Also visit my blog post: Adrian
7 October 2025 23:06
#1388   Tammara
      
steroids that start with a

References:


travelersqa.com
7 October 2025 22:36
#1387   Brandi
      
My webpage: PokerTube
7 October 2025 21:40
#1386   Jerry
      
7 October 2025 21:30
#1385   Tia
      
steroid uses

References:


ajarproductions.com
7 October 2025 20:24
#1384   Lorenza
      
best stack of supplements for gaining muscle

References:


https://cuwip.ucsd.edu/members/hockeypaul2/activity/2029281
7 October 2025 16:09
#1383   Cara
      
best muscle pills 2015

References:


forum.issabel.org
7 October 2025 15:33
#1382   Christin
      
my web page: play Poker
Online
7 October 2025 14:52
#1381   Lloyd
      
Feel free to visit my blog post; highstakes 777 Login
7 October 2025 13:20
#1380   Julian
      
clen vs anavar

References:


https://output.jsbin.com/tagayatade/
7 October 2025 12:16
#1379   Tyson
      
Some really excellent content on this web site, regards for contribution.

Here is my homepage highstake
7 October 2025 09:07
#1378   Ellen
      
Here is my web blog :: Watch Free
Poker Tv Shows
7 October 2025 05:40
#1377   Tyrell
      
7 October 2025 04:37
#1376   Adolph
      
Feel free to surf to my website - high stakes poker
7 October 2025 04:19
#1375   Justin
      
Review my web site: poker
online
7 October 2025 03:43
#1374   Lauri
      
BPC‑157 is a synthetic peptide that has attracted attention for its potential
to accelerate tissue repair and reduce inflammation. It is derived from a
fragment of body protective compound 157, which is naturally
present in the stomach lining. Users report that BPC‑157 may help heal muscle strains, tendon injuries,
ligament damage, and even gastrointestinal ulcers.
The peptide’s mechanism involves stimulating angiogenesis
(the formation of new blood vessels), enhancing growth factor production, and
modulating inflammatory pathways. Because it is a relatively short peptide chain, it can be administered either
orally or via injection, with each route offering distinct advantages and limitations.




BPC‑157: Benefits, Side Effects, Dosage, and More

The primary benefit touted by users and some preliminary animal studies is rapid recovery
from soft tissue injuries. Muscle healing appears to improve within days rather than weeks, and joint pain can diminish significantly
after consistent use. In addition to musculoskeletal support, BPC‑157 has been shown in laboratory settings to protect the gut mucosa against damage
caused by NSAIDs or alcohol, potentially making it useful for individuals with inflammatory bowel disease or
those who experience gastric distress from chronic
medication use.

Side effects reported are generally mild. Some people notice a slight increase in heart rate or transient flushing when first starting therapy.
Rarely, users describe headaches or minor dizziness. Because
BPC‑157 is not yet approved by major regulatory bodies for human consumption, data
on long‑term safety remain limited. It is advised to
monitor for any unusual symptoms and discontinue if they persist.



Dosage varies depending on the administration method.
For oral capsules, typical regimens range from 200 µg to
400 µg per day, taken with meals to improve absorption. Oral users often report a
gradual onset of benefits over one to two weeks. Injection protocols are more concentrated; many practitioners
use 0.5 mg per injection administered subcutaneously or intramuscularly, typically three times per week for four to six weeks.
Some athletes adopt a tapering schedule after the initial period to maintain gains while minimizing exposure.




BPC‑157: Benefits, Side Effects, Dosage, and More

When comparing oral versus injectable forms, absorption kinetics differ markedly.

Oral BPC‑157 must survive gastric acid and enzymatic breakdown, so its bioavailability is lower than that of injected peptide.
Nevertheless, studies in rodents have shown that even low oral doses can reach
systemic circulation, possibly through a transcytosis mechanism across the intestinal epithelium.

Users who prefer convenience or wish to avoid needles often choose oral
supplements despite the slower onset.

Injectable BPC‑157 delivers the peptide directly into the bloodstream or local tissues, providing higher
peak concentrations and faster therapeutic effects. However, injections require
sterile technique and may pose a risk of infection if not
performed correctly. Additionally, injection sites can sometimes develop localized irritation or
mild scarring after repeated use. Some protocols recommend
alternating injection sites to reduce tissue damage.


Both routes share common side effect profiles, but the intensity may vary
with dosage. High-dose oral regimens (above 400 µg per day) have been associated in anecdotal reports with increased
blood pressure or mild tachycardia, though these findings are not universally
observed. In contrast, large single injections (>1 mg)
can occasionally trigger transient swelling or soreness at the injection site.




Effects on Cancer Patients

The influence of BPC‑157 on cancer biology remains an area of active research.
Preclinical studies have suggested that the peptide may modulate tumor microenvironments by altering angiogenic factors
and inflammatory cytokines, potentially inhibiting metastasis in certain models.
However, other investigations raise concerns that enhanced blood vessel growth could inadvertently support tumor nourishment, leading to accelerated progression in some cancer
types. Because of these conflicting findings, BPC‑157 is not recommended
for individuals undergoing active cancer treatment without
close medical supervision.

Some clinicians have explored BPC‑157 as a supportive therapy to mitigate side
effects from chemotherapy or radiation, such as mucositis or intestinal damage.
Early reports indicate that patients receiving low-dose oral BPC‑157
experienced reduced gastrointestinal discomfort and improved appetite.
Nonetheless, the evidence is preliminary; randomized controlled
trials are needed to confirm efficacy and safety in oncology
settings.




In summary, BPC‑157 offers promising benefits for tissue repair and anti-inflammatory effects,
with oral use providing convenience at a slower onset and injectable administration delivering rapid, higher concentrations.
Side effect profiles remain mild but warrant monitoring, especially at higher doses or when used repeatedly.

For cancer patients, the peptide’s impact is
still uncertain; it may aid in managing treatment side effects while potentially
influencing tumor dynamics, making careful evaluation essential before
incorporation into care plans.

References:


capsules
7 October 2025 00:50
#1373   Kisha
      
Here is my web-site; Online
poker Tournaments
6 October 2025 21:53
#1372   Lan
      
6 October 2025 21:43
Add Comments

Name:*
E-Mail:
  Geo Keyboard  
 

Dear reader, guardian.ge welcomes your comments. Please express your views on topic and be respectful of others.

bold italic underline strike | align left centered align right | Ensert smilies insert linkInsert protected URL Choice the color | hidden text insert quote Convert selected text from transliteration to Cyrillic alphabet Insert spoiler

Code: *


Back1 ... 57 58 59 60 61 62 63 64 65 ... 130Next